Haemonetics (FRA:HAZ) Gross-Profit-to-Asset % : 33.44% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Haemonetics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Haemonetics's annualized Gross Profit for the quarter that ended in Dec. 2023 was €652 Mil. Haemonetics's average Total Assets over the quarter that ended in Dec. 2023 was €1,951 Mil. Therefore, Haemonetics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 33.44%.

Haemonetics Gross-Profit-to-Asset % Historical Data

The historical data trend for Haemonetics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Gross-Profit-to-Asset % Chart

Haemonetics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

34.67

38.55

24.98

28.53

32.87

Haemonetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															32.78	32.61	34.13	34.58	33.44

Competitive Comparison of Haemonetics's Gross-Profit-to-Asset %

For the Medical Instruments & Supplies subindustry, Haemonetics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haemonetics's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Haemonetics's Gross-Profit-to-Asset % falls into.

Haemonetics Gross-Profit-to-Asset % Calculation

Haemonetics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Mar. 2022 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	574.501	/	( (1688.638	+	1807.127)	/ 2 )
	=	574.501	/	1747.8825
	=	32.87 %

Haemonetics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	652.416	/	( (1884.565	+	2017.792)	/ 2 )
	=	652.416	/	1951.1785
	=	33.44 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Haemonetics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Haemonetics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (FRA:HAZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (FRA:HAZ) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

HAE:USA HAZ:Germany

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics (FRA:HAZ) Headlines

No Headlines